Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: Preliminary results

Journal of Nuclear Medicine

Volumn 53, Issue 2, 2012, Pages 255-263

  Garin, Etienne ^a,b,c   Lenoir, Laurence ^a   Rolland, Yan ^a   Edeline, Julien ^a,b   Mesbah, Habiba ^a   Laffont, Sophie ^a,c   Porée, Philippe ^a   Clément, Bruno ^c   Raoul, Jean Luc ^d   Boucher, E ^a,c  

^a CS 44229   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c INSERM   (France)

^d INSTITUT PAOLI CALMETTES   (France)

Author keywords

90y, dosimetry; Hepatocellular carcinoma; Radioembolization

Indexed keywords

ALBUMIN TC 99M; ALPHA FETOPROTEIN; IODINATED POPPYSEED OIL; IODINE 131; MACROSALB I 131; MICROSPHERE; YTTRIUM 90; DIAGNOSTIC AGENT; GLASS; MACROSALB TC 99M; YTTRIUM;

AGED; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DOSIMETRY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEPTICEMIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; ARTIFICIAL EMBOLISM; CHEMISTRY; LIVER TUMOR; METHODOLOGY; RADIOMETRY; SCINTISCANNING; SURVIVAL; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; GLASS; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOMETRY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84856770809     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.094235     Document Type: Article

References (14)

1. El-Serag HB. Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750. (Pubitemid 29114292)
2. Salem R, Thurston KG, Carr BI, et al. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13:S223-S229.
3. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-1928.
4. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.
5. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52:1741-1749.
6. Salem R, Lewandowski RJ, Gates VL, et al. Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265-278.
7. Garin E, Rolland Y, Lenoir L, et al. Utility of quantitative Tc-MAA SPECT/CT for yttrium-labelled microsphere treatment planning: calculating vascularized hepatic volume and dosimetric approach. Int J Mol Imaging. July 28, 2011 [Epub ahead of print].
8. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616-623.
9. Sato KT, Omary RA, Takehana C, et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol. 2009;20:1564-1569.
10. 90Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55:168-197.
11. Becker S, Laffont S, Rolland Y, et al. Dosimetric evaluation and therapeutic response to vectorized internal radiation therapy of hepatocarcinomas using iodine-131 labelled lipiodol. Nucl Med Commun. 2008;29:815-825.
12. Ettorre GM, Santoro R, Puoti C, et al. Short-term follow-up of radioembolization with yttrium-90 microspheres before liver transplantation: new perspectives in advanced hepatocellular carcinoma. Transplantation. 2010;90:930-931.
13. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. 2009;10:25-34.
14. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.